Page 117 - 2018_09-Mondo
P. 117
Real world venetoclax experience
References
1. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311-22.
2. Anderson M, Tam C, Lew T, Juneja S, Juneja M, Westerman D, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 2017; 129(25):3362-70.
3. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour J, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768-78.
4. Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018; 12;131(15):1704-11.
5. Jones J, Mato A, Wierda W, Davids M, Choi M, Cheson B, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicen- tre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65-75.
6. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-20.
7. Mato A, Nabhan C, Barr P, Ujjani C, Hill B, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199-205.
8. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Annals of oncology : offi- cial journal of the European Society for Medical Oncology. 2017;28(5):1050-6.
9. Forum UC. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016; 101(12): 1563-72.
10. Mato AR, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, et al. Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies. Blood 2017; 130(Supp 1):3011.
11. Barrientos JC, Kaur M, Mark A, Chung J, Driscoll N, Bender A, et al. Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation. Blood. 2015;126(23): 4155.
12. Hallek M, Cheson B, Catovsky D, Caligaris- Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group
1996 guidelines. 2008;111(12):5445-56.
13. FDA. Highlights of Prescribing
Information: Venclexta. 2018.
14. Howard S, Jones D, Pui C. The tumor lysis
syndrome. N Engl J Med. 2011;
364(19):1844-54.
15. Bland J, Altman D. Survival probabilities
(the Kaplan-Meier method). BMJ. 1998;
317(7172):1572.
16. Matthews D, Farewell V. 7 The Log-Rank
or Mantel-Haenszel Test for the Comparison of Survival Curves In: Basel S, Karger A, eds. Using and Understanding Medical Statistics 2007:67-75.
17. Anderson P, Gill R. Cox’s regression model for counting processes: a large sample study. Ann Statist. 1982;10(4):1100-20.
18. Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, et al. Integrated analysis: outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL?SLL) with high-risk Prognostic Factors. Hematological Oncology. 2017; 35(S2):109-11.
19. Mato A, Wierda W, Davids M, Cheson B, Coutre S, Choi M, et al. Analysis of PET- CT to Identify Richter’s Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. ASH Abstract 817;2017.
20. Mato A, Nabhan C, Thompson M, Lamanna N, Brander D, Hill B, et al. Toxicities and outcomes of 616 ibrutinib- treated patients in the United States: a real- world analysis. Haematologica. 2018; 103(5):874-9.
haematologica | 2018; 103(9)
1517
